2025.Apr.23

Corporate

OBI-822 Completes Second Interim Analysis of Phase III Trial
OBI Announces Trial Termination, Refocuses Resources on ADC Development

TAIPEI, Taiwan, April 23, 2025 — OBI Pharma (4174.TWO) today announced that the Phase III clinical trial of its active cancer immunotherapy, Adagloxad Simolenin (OBI-822)/OBI-821, for the treatment of triple-negative breast cancer (TNBC), has completed its second interim analysis.

HOMEWhat’s NewNewsOBI-822 Completes Second Interim Analysis of Phase III Trial OBI Announces Trial Termination, Refocuses Resources on ADC Development

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Apr.23

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science.